STSG-0002

STSG-0002 is an investigational gene therapy developed for the treatment of chronic hepatitis B. It is based on adeno-associated virus (AAV) vector technology and utilizes RNA interference to inhibit hepatitis B surface antigen (HBsAg) expression. The drug was initially developed by Staidson (Beijing) Biopharmaceuticals and is designed to provide long-lasting efficacy with a single administration, distinguishing it from non-viral small nucleic acid therapies that require repeated dosing. Clinical trials reached up to Phase 2 before being terminated or discontinued[1][5][7]. The primary mechanism of action involves inhibition of HBsAg, aiming to reduce viral load and improve disease outcomes in patients with chronic hepatitis B.